On November 3-5, 2014, Suzanne Durrell participated in the Fifteenth Annual Pharma Congress. The Pharma Congress, or formally the Pharmaceutical Regulatory and Compliance Congress and Best Practices Forum, to be more formal is a coalition of senior compliance professionals and legal counsel from more than 50 of the largest research based pharmaceutical manufacturers.
Suzanne Durrell joined the Pharma Congress Qui Tam panel and presented her paper, Corporate Integrity Agreements can be the basis for a False Claims Act Case. Her paper concerns when violation of a corporate integrity agreement, regularly required as part of health care fraud settlements, give rise to False Claims Act liability.
CIA provisions raise the issue of when, if ever, violation of a CIA can give rise to liability under the False Claims Act, 31 U.S.C. §§ 3729, et. seq. Of particular relevance is 31 U.S.C. § 3729(a)(7), as amended an renumbered as § 3729(a) (1)(G) by the Fraud Enforcement & Recovery Act of 2009, § 4(b)(3), 123 Stat. at 1623 (May 20, 2009) (“FERA”).
The Pharma Congress is by far the largest annual gathering of pharmaceutical company compliance professional and in-house counsel. It is attended by approximately 400 annually. The Pharmaceutical Compliance Forum promotes effective corporate compliance programs. The members meet twice a year, for two days. And they focus on open and informal sharing of compliance information, best practices, and current developments in the field.
PCF also sponsors a three-day compliance congress each Fall. Learn more.
